Ardelyx Inc.

1.59+0.0671+4.41%Vol 20.79M1Y Perf -75.25%
Jul 27th, 2021 15:18 DELAYED
BID1.58 ASK1.59
Open1.56 Previous Close1.52
Pre-Market1.55 After-Market-
 0.03 1.97%  - -
Target Price
7.08 
Analyst Rating
Strong Buy 1.00
Potential %
342.50 
Finscreener Ranking
★★★     50.44
Insiders Trans % 3/6/12 mo.
-100/-100/-93 
Value Ranking
★★+     49.78
Insiders Value % 3/6/12 mo.
-100/-100/-39 
Growth Ranking
★★     45.92
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-39 
Income Ranking
 —    -
Market Cap156.66M 
Earnings Rating
Sell
Price Range Ratio 52W %
1.00 
Earnings Date
5th Aug 2021

Today's Price Range

1.511.68

52W Range

1.519.23

5 Year PE Ratio Range

-5.40-5.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-24.38%
1 Month
-81.16%
3 Months
-82.24%
6 Months
-77.97%
1 Year
-75.25%
3 Years
-61.03%
5 Years
-85.93%
10 Years
-

TickerPriceChg.Chg.%
ARDX1.590.06714.41
AAPL146.63-2.3600-1.58
GOOG2 730.95-61.9400-2.22
MSFT285.56-3.4900-1.21
XOM57.68-0.8000-1.37
WFC45.150.14000.31
JNJ172.260.39000.23
FB366.37-6.0900-1.64
GE13.110.19001.47
JPM151.52-0.1300-0.09
Financial StrengthValueIndustryS&P 500US Markets
4.40
4.90
0.21
0.40
-20.70
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
91.20
-774.70
-761.20
-
-
RevenueValueIndustryS&P 500US Markets
11.10M
0.11
-21.55
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.32-0.34-6.25
Q04 2020-0.26-0.32-23.08
Q03 2020-0.28-0.2028.57
Q02 2020-0.27-0.28-3.70
Q01 2020-0.27-0.257.41
Q04 2019-0.34-0.2817.65
Q03 2019-0.38-0.372.63
Q02 2019-0.39-0.41-5.13
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.36-9.09Negative
9/2021 QR-0.290.00-
12/2021 FY-1.43-7.52Negative
12/2022 FY-0.82-51.85Negative
Next Report Date5th Aug 2021
Estimated EPS Next Report-0.36
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume20.79M
Shares Outstanding98.71M
Trades Count30.51K
Dollar Volume4.99M
Avg. Volume3.66M
Avg. Weekly Volume25.06M
Avg. Monthly Volume15.96M
Avg. Quarterly Volume6.38M

Ardelyx Inc. (NASDAQ: ARDX) stock closed at 1.62 per share at the end of the most recent trading day (a -9.52% change compared to the prior day closing price) with a volume of 20.35M shares and market capitalization of 156.66M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 88 people. Ardelyx Inc. CEO is Michael G. Raab.

The one-year performance of Ardelyx Inc. stock is -75.25%, while year-to-date (YTD) performance is -76.51%. ARDX stock has a five-year performance of -85.93%. Its 52-week range is between 1.51 and 9.23, which gives ARDX stock a 52-week price range ratio of 1.00%

Ardelyx Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 1.27, a price-to-sale (PS) ratio of 14.93, a price to cashflow ratio of 58.30, a PEG ratio of 2.32, a ROA of -45.63%, a ROC of -50.38% and a ROE of -67.97%. The company’s profit margin is -%, its EBITDA margin is -761.20%, and its revenue ttm is $11.10 Million , which makes it $0.11 revenue per share.

Of the last four earnings reports from Ardelyx Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.36 for the next earnings report. Ardelyx Inc.’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for Ardelyx Inc. is Strong Buy (1), with a target price of $7.08, which is +342.50% compared to the current price. The earnings rating for Ardelyx Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Ardelyx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Ardelyx Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.54, ATR14 : 0.56, CCI20 : -139.31, Chaikin Money Flow : -0.03, MACD : -1.42, Money Flow Index : 35.95, ROC : -79.49, RSI : 12.50, STOCH (14,3) : 1.05, STOCH RSI : 0.00, UO : 15.93, Williams %R : -98.95), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Ardelyx Inc. in the last 12-months were: David M. Mott (Buy at a value of $1 000 841), David P. Rosenbaum (Sold 43 931 shares of value $255 973 ), Elizabeth Grammer (Option Excercise at a value of $97 440), Elizabeth Grammer (Sold 71 314 shares of value $464 643 ), Jeffrey Jacobs (Option Excercise at a value of $4 050), Jeffrey Jacobs (Sold 113 759 shares of value $658 821 ), Justin A. Renz (Sold 4 322 shares of value $24 557 ), Michael G. Raab (Sold 108 871 shares of value $613 725 ), Robert Blanks (Sold 42 490 shares of value $245 993 ), Susan Rodriguez (Sold 6 698 shares of value $41 369 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Ardelyx Inc.

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

CEO: Michael G. Raab

Telephone: +1 510 745-1700

Address: 34175 Ardenwood Boulrvard, Fremont 94555, CA, US

Number of employees: 88

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

83%17%

Bearish Bullish

68%32%

Bearish Bullish

60%40%

News

Stocktwits